These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30294857)

  • 21. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Left atrial volume and function in dogs with naturally occurring myxomatous mitral valve disease.
    Höllmer M; Willesen JL; Tolver A; Koch J
    J Vet Cardiol; 2017 Feb; 19(1):24-34. PubMed ID: 27825670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QT instability, an indicator of augmented arrhythmogenesis, increases with the progression of myxomatous mitral valve disease in dogs.
    Brüler BC; Jojima FS; Dittrich G; Giannico AT; Sousa MG
    J Vet Cardiol; 2018 Aug; 20(4):254-266. PubMed ID: 30031743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tricuspid annular plane systolic excursion in dogs with myxomatous mitral valve disease with and without pulmonary hypertension.
    Poser H; Berlanda M; Monacolli M; Contiero B; Coltro A; Guglielmini C
    J Vet Cardiol; 2017 Jun; 19(3):228-239. PubMed ID: 28579307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Müller S; Menciotti G; Borgarelli M
    J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of global and regional left ventricular volume and shape by real-time 3-dimensional echocardiography in dogs with myxomatous mitral valve disease.
    Ljungvall I; Höglund K; Carnabuci C; Tidholm A; Häggström J
    J Vet Intern Med; 2011; 25(5):1036-43. PubMed ID: 21848946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of admission lactate concentration, lactate variables, and shock index in outcome assessment in dogs diagnosed with shock.
    Zollo AM; Ayoob AL; Prittie JE; Jepson RD; Lamb KE; Fox PR
    J Vet Emerg Crit Care (San Antonio); 2019 Sep; 29(5):505-513. PubMed ID: 31290240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
    Troia R; Sabetti MC; Crosara S; Quintavalla C; Romito G; Mazzoldi C; Fidanzio F; Cescatti M; Bertazzolo W; Giunti M; Dondi F
    J Vet Intern Med; 2022 Nov; 36(6):2053-2062. PubMed ID: 36196592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Longitudinal Outcome Of Canine (K9) myxomatous mitral valve disease (LOOK-Mitral registry): Baseline characteristics.
    Franchini A; Borgarelli M; Abbott JA; Menciotti G; Crosara S; Häggström J; Lahmers S; Rosenthal S; Tyrrell W
    J Vet Cardiol; 2021 Aug; 36():32-47. PubMed ID: 34062479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.
    Rešetar Maslov D; Farkaš V; Rubić I; Kuleš J; Beletić A; Beer Ljubić B; Šmit I; Mrljak V; Torti M
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective evaluation of plasma lactate parameters for prognosticating dogs with shock.
    Blutinger AL; Zollo AM; Weltman J; Prittie J
    J Vet Emerg Crit Care (San Antonio); 2021 May; 31(3):351-359. PubMed ID: 33709568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Echocardiographic anatomy of the mitral valve in healthy dogs and dogs with myxomatous mitral valve disease.
    Wesselowski S; Borgarelli M; Menciotti G; Abbott J
    J Vet Cardiol; 2015 Jun; 17(2):97-106. PubMed ID: 26003902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK; Atkins CE; Eriksson A; Hess AM
    J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma and platelet serotonin concentrations in healthy dogs and dogs with myxomatous mitral valve disease.
    Mangklabruks T; Surachetpong SD
    J Vet Cardiol; 2014 Sep; 16(3):155-62. PubMed ID: 25127665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of radiographic measurements to diagnose stage B2 preclinical myxomatous mitral valve disease in dogs.
    Stepien RL; Rak MB; Blume LM
    J Am Vet Med Assoc; 2020 May; 256(10):1129-1136. PubMed ID: 32364449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of genes associated with human myxomatous mitral valve disease in dogs with familial myxomatous mitral valve degeneration.
    Meurs KM; Friedenberg SG; Williams B; Keene BW; Atkins CE; Adin D; Aona B; DeFrancesco T; Tou S; Mackay T
    Vet J; 2018 Feb; 232():16-19. PubMed ID: 29428085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation.
    Disatian S; Ehrhart EJ; Zimmerman S; Orton EC
    J Heart Valve Dis; 2008 Jul; 17(4):402-11; discussion 412. PubMed ID: 18751470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of heart rate turbulence in dogs with myxomatous mitral valve disease.
    Dos Santos JP; Lucina SB; da Costa BN; Olaguivel KLC; Tuleski GLR; Sousa MG
    Open Vet J; 2021; 11(4):635-644. PubMed ID: 35070858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease.
    Kim HS; Kang JH; Jeung EB; Yang MP
    J Vet Intern Med; 2016 Sep; 30(5):1589-1600. PubMed ID: 27573621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.